The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).
 
Danka Sinikovic Zebic
Speakers' Bureau - Merck
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Andrew James Martin
No Relationships to Disclose
 
Farzana D. Pashankar
Consulting or Advisory Role - Novartis
 
Danish Mazhar
No Relationships to Disclose
 
Robert A Huddart
Leadership - Cancer clinic london Limited liability partnership
Consulting or Advisory Role - Bayer; Gilead Sciences; Janssen Oncology; Merck Sharp & Dohme; Nektar; Roche
Speakers' Bureau - Bristol Myers Squibb Foundation; Pfizer
Research Funding - Astellas Pharma (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for dug discovery from Janssen (Inst)
Travel, Accommodations, Expenses - Nektar; Roche/Genentech
 
Matthew Wheater
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; MSD; Pfizer; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Healthcare at Home; Novartis
Research Funding - AVEO (Inst); GlaxoSmithKline/Novartis (Inst); GlaxoSmithKline/Novartis (Inst); MSD (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; Novartis
 
Euan Thomas Walpole
No Relationships to Disclose
 
Elaine Dunwoodie
No Relationships to Disclose
 
Darren R. Feldman
Consulting or Advisory Role - BioNTech; Cigna
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Telix Pharmaceuticals
Other Relationship - UpToDate
 
Alison Jane Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Bristol-Myers-Squib; Janssen Oncology; Merck Serono; Pfizer; Roche; Sanofi
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer
Research Funding - Genzyme
 
David Wyld
Consulting or Advisory Role - Ipsen; Novartis; Novartis
Speakers' Bureau - Ipsen
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen; Ipsen; Ipsen; Ipsen; MSD Oncology; Novartis; Novartis; Novartis
 
Nicola Jane Lawrence
No Relationships to Disclose
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Peter S. Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Epizyme (Inst); Genentech (Inst); Janssen-Cilag (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)